Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models is a research paper published in International Journal of Pharmaceutics X (2020). On theSindex it has a DataRank of 0. It has been cited 21 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: U54 CA233396
NIMHD NIH HHS
Grant: U54 MD007582
National Institutes of Health
Grant: U54CA233396-02
National Institutes of Health
Grant: 5U54CA233396-03
1/3 Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
National Cancer Institute
FWCI
0.91
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer
Additional file 1 of Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer
Additional file 2 of Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer
Additional file 2 of Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer
Additional file 1 of Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer
Additional file 1 of Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer